Genzyme Raises Bid For AnorMED, Emphasizing Market Advantage For Mozobil
This article was originally published in The Pink Sheet Daily
Executive Summary
Latest bid is 12.5% higher than Millennium’s, but the firm will have three days to match it if needed.